Search Results - subject_exact:"Pharmaindustrie"

Incentives, surrogates, and long-run vaccination

Campos-Mercade, Pol; Meier, Armando N.; Meier, Stephan; … - 2026

Can monetary incentives improve health behaviors in the long run, and do commonly used surrogate outcomes capture these effects? We study these questions in the context of vaccination using a large-scale field experiment. The experiment combines commonly used surrogates-vaccination intentions,...

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015654644

Show one more version 1

Incentives, surrogates, and long-run vaccination

Campos Mercade, Pol; Meier, Armando N.; Meier, Stephan; … - 2026

Book / Working Paper

Cognitive supply chain management and risk management in pharmaceuticals : the mediating roles of forecasting, synchronization, and transparency

Abushaikha, Ismail; AlQahtani, Munirah; Bwaliez, Omar M.; … - 2026

Background: This study examines the degree to which cognitive supply chain management (CSCM) indirectly enhances supply chain risk management (SCRM), addressing the lack of specific empirical research concerning the underlying mechanisms of this relationship. Specifically, this study tests the...

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015611796

Artificial intelligence adoption for pharmaceutical salesforce performance : a case study in Kuwait

Abdallah, Wael; Aziza, Mulham; Chamas, Hassan Baz - 2026

Purpose - The research aims to investigate the factors influencing the adoption of artificial intelligence (AI) in pharmaceutical industry companies, specifically focusing on its impact on salesforce performance. Design/methodology/approach - We collected research data from pharmaceutical...

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015592497

Timely access to new pharmaceuticals in Canada, the United States, and the European Union, 2026

Acri, Kristina M. L.; Assad, Lauren - 2026

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015613516

Decoding drug search under public funding : rates, directions, and social impacts in an agent-based model

Dosi, Giovanni; Palagi, Elisa; Roventini, Andrea; … - 2026

By extending the framework presented by Dosi et al. (2023b), we build an evolutionary agent-based model of the pharmaceutical sector featuring a government and a Public Research Lab investing in R&D and innovating across different therapeutic areas. After having empirically validated our...

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015614624

Preventing drug shortages through improved demand fulfillment : the untapped potential of postponement and flexibility

Blossey, Gregor; Hahn, Gerd J.; Koberstein, Achim - 2026

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015605913

Should we own a plantation? : German pharmaceutical companies, resource security, and cinchona production in the Dutch East Indies, 1870-1913

Oestermann, Tristan - 2026

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015620724

Risk management of market entry early Korean-German business cooperation in the pharmaceutical industry, 1957-1972

Eichert, Thomas - 2026

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015620761

Barriers to Industry 4.0 adoption in pharmaceutical manufacturing companies : a case study

Strüssmann, Breno; Hvam, Lars; Haug, Anders - 2026

Purpose: This study explores the barriers to adopting Industry 4.0 technologies within the pharmaceutical manufacturing sector. Despite the potential for transformative benefits, the sector has been slow in embracing these technologies due to unique regulatory and operational challenges. This...

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015627292

Pharmaceutical advertising in dynamic equilibrium

Dubois, Pierre; Pakes, Ariel - 2026

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015637921

Show 2 more versions 2

Pharmaceutical advertising in dynamic equilibrium

Dubois, Pierre; Pakes, Ariel - 2026

Book / Working Paper

Pharmaceutical Advertising in Dynamic Equilibrium

Dubois, Pierre; Pakes, Ariel - 2026

Book / Working Paper

A tale of three industries : the rise, decline and rise again of the Swedish life sciences sector

Abdi, Ismail; Dugo, Andrea; Erixon, Fredrik; Guinea, Oscar - 2026

In this report we show that the Swedish life sciences sector has changed remarkably in the past 30 years and that is yet again positioned for rapid growth. We identify three distinct phases of the development in the last three decades - rise, decline, and rise again. Compared to 30 years ago,...

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015638643

Therapeutic substitutability under scrutiny : defining relevant markets in EU pharmaceutical law

Kaushik, Kanika - 2026

Market definition is fundamental to EU competition law. It serves as a preliminary step in assessing dominance, anti-competitive conduct, and merger control. With respect to the pharmaceutical sector, traditional approaches to defining the relevant market face specific hurdles. Therapeutic...

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015638991

The application of EU competition law to reverse payment patent settlements in the pharmaceutical sector : current status under article 101 TFEU

Campiglia, Alessandra - 2026

Over the past few decades, the pharmaceutical sector has witnessed the occurrence of a particular type of agreement used to settle patent disputes between originator and generic drug manufacturers: so-called reverse payment patent settlements, also known as pay-for-delay agreements. Due to their...

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015638993

Blockchain-enabled traceability in pharmaceutical supply chains : a mapping review of evidence for visibility, anti-counterfeiting, and chain-of-custody control

Diaz, Félix; Cerna, Nhell; Liza, Rafael; Motta, Bryan; … - 2026

Background: Blockchain is increasingly proposed to strengthen pharmaceutical traceability, anti-counterfeiting, and chain of custody in multi-actor supply chains, but the evidence base remains heterogeneous in technical rigor and operational clarity. Methods: We conducted a mapping review of...

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015647687

Biopharmaceutical innovation: corporate governance for equitable global health

Gehl Sampath, Padmashree; Tulum, Öner; Lazonick, William - 2026

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015639806

An analysis of implementing pharmaceutical cost-containment measures in Egypt : lessons from international experiences

Nassar, Heba; Reda, Dalia - 2026

Purpose - The main goal of this paper is to analyze the implementation of pharmaceuticals cost-containment measures in Egypt. Design/methodology/approach - This paper adopts descriptive and analytical techniques to assess the extent of implementing pharmaceutical cost-containment measures in...

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015560586

Upstream innovation effect of downstream competition : how does volume-based procurement shape pharmaceutical innovation strategies?

Zheng, Yanghui; Shan, Fenxia; Zhou, Shengjia - 2026

This study examines how volume-based procurement policies reconfigure innovation trajectories in pharmaceutical enterprises from a knowledge-based perspective. Analysing panel data from listed pharmaceutical companies, this research shows that this procurement mechanism triggers a strategic...

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015676144

Reform-induced competition : evaluating the impact on Swiss pharmacies and total drug costs

Anderes, Marc - 2026

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015673711

Competition matters : uniform vs. indication-based pricing of pharmaceuticals

Brekke, Kurt R.; Dalen, Dag Morten; Straume, Odd Rune - 2026

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015675103

Show one more version 1

Competition matters : uniform vs. indication-based pricing of pharmaceuticals

Brekke, Kurt R.; Dalen, Dag Morten; Straume, Odd Rune - 2025

Book / Working Paper

Comparative trade performance of India's pharmaceutical industry and leading global exporters : a multi-index analysis at the sectoral and product levels

Arif, Mohd; Mohammad, Aas; Alomair, Abdulrahman; … - 2026

This study examines the comparative trade performance of India's pharmaceutical industry vis-à-vis leading global pharmaceutical exporters, particularly the United States, Germany, and Switzerland, over the period 2005-2024, using sectoral (HS 30) and product-level (HS 3001-3006) trade data....

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015676750

Bürokratielasten aus Sicht der deutschen Chemie -, Pharma - und kunststoffverarbeitenden Industrie: Befragungsergebnisse und Handlungsempfehlungen

Röhl, Klaus-Heiner; Schmitz, Edgar; Lammers, Miriam - 2026

Persistent link: https://ebvufind01.dmz1.zbw.eu/10016060190

Leveraging knowledge graphs in pharmaceutical supply chains : insights into key drivers of drug shortages

Eberhardt, Katharina; Schwärzel, Amelie; Kaiser, … - 2025

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015547235

Investigating demand forecasting practices and challenges in Ghana's manufacturing pharmaceutical (MPharma) small and medium enterprises (SMEs) : insights and recommendations

Aidoo-Anderson, Albert; Polychronakis, Yiannis; … - 2025

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015549049

Pharmaceuticals and digital health : evidence from data-driven insights on the insulin market

Bignon, Léa - 2026

Persistent link: https://ebvufind01.dmz1.zbw.eu/10016060618

Bürokratielasten aus Sicht der deutschen Chemie -, Pharma - und kunststoffverarbeitenden Industrie : Befragungsergebnisse und Handlungsempfehlungen

Röhl, Klaus-Heiner; Schmitz, Edgar; Lammers, Miriam - 2026 - Stand: Juni 2026

Die Unternehmen der Chemieindustrie, der pharmazeutischen Industrie und der kunststoffverarbeitenden Industrie sind durch staatliche Bürokratie hoch belastet. Es gibt zahlreiche fertigungs- und produktspezifische Regulierungen, etwa mit der europäischen REACH-Verordnung im Chemikalienrecht,...

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015670864

Long-term performance of technology acquisitions : the role of acquisition program diversity, innovation, and alliance portfolio size : evidence from the pharmaceutical industry

Schweizer, Lars; Wang, Le; Koscher, Eva - 2025

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015333120

Exploring corporate capital structure and overleveraging in the pharmaceutical industry

Issa, Samar; Issa, Hussein - 2025

This paper applies an empirical model of corporate capital structure, optimal debt, and overleveraging to estimate overleveraging measured as the difference between actual and optimal debt. Estimated using a sample of the twenty largest pharmaceutical firms, covering the time span from 2000 to...

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015333730

Free entry and social inefficiency in regulated pharmacy markets

Jokelainen, Antto; Markkanen, Jaakko; Leppälä, Samuli; … - 2025 - [Updated] April 2025

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015486104

Show one more version 1

Free entry and social inefficiency in regulated pharmacy markets

Jokelainen, Antto; Markkanen, Jaakko; Leppälä, Samuli; … - 2025

Book / Working Paper

Greening the pharmaceutical supply chain

Belal, Md Mostain; Shukla, Vinaya; Sreejith Balasubramanian - 2025

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015357789

Evaluation of a partial ban of Rx-rebates in Germany using difference-in-differences

Gail, Maximilian M.; Goetz, Georg; Herold, Daniel; … - 2025

In December 2020, Germany implemented a policy restricting online pharmacies from offering rebates on prescription drugs to members of the statutory health insurance. This policy change created a natural experiment, allowing us to analyze its impact on the pharmaceutical market using...

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015202669

The threat of pharmaceutical crime in the EU and beyond

2025

This report outlines the threat of pharmaceutical crime in the EU and beyond, as assessed by Europol. It aims to raise awareness of the ways criminal networks exploit consumers and industry in generating illegal revenue through producing and selling counterfeit medicines.

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015322789

Integrated shelf-life rules for multi-level pharmaceutical tablets manufacturing processes

Simonis, Michael; Nickel, Stefan - 2025

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015198531

The EU community pharmacy market : the density and its influencing factors

Schwaabe, Selina - 2025

Community pharmacies deliver high-quality health care and are responsible for medication safety. The goal of the government is to ensure nationwide, accessible, and affordable medical health-care services provided by pharmacies. Therefore, the per capita density of community pharmacies matters....

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015211718

An assessment of the implications of distribution remuneration and taxation policies on the final prices of prescription medicines : evidence from 35 countries

Leon, Giovanny; Carbonel, Christophe; Rampuria, Aparajit; … - 2025

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015394765

Combating vaccine hesitancy : the case of HPV vaccination

Díaz, Lina; Martínez, Déborah; Márquez, Karina; … - 2025

Cervical cancer, primarily caused by persistent Human Papillomavirus (HPV) infection, remains one of the leading causes of cancer-related deaths among women in developing countries. Although HPV vaccines are widely available in these regions, vaccine uptake remains persistently low. To address...

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015271625

Research on the relationship between R&D investment, corporate governance and corporate performance : an empirical analysis based on listed pharmaceutical manufacturing enterprises

Wan, Dongqi; Yang, Yao; Kong, Yuanfei - 2025

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015466488

Role of pharmacists in generic pharmaceutical adoption

Kakehi, Haruo; Nakajima, Ryo - 2025

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015187356

Show one more version 1

Role of pharmacists in generic pharmaceutical adoption

Kakehi, Haruo; Nakajima, Ryo - 2024

Book / Working Paper

Drug pricing models, no "one-size-fits-all" approach : a systematic review and critical evaluation of pricing models in an evolving pharmaceutical landscape

Manders, Evert A.; Berg, Sibren van den; Visser, Saco J. de - 2025

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015448455

Passthrough of retail price regulation in the market for pharmaceuticals

Jaakko, Markkanen - 2025

I study the passthrough of regulated ad valorem pharmacy markups and reduced Value Added Tax (VAT) rates to pharmaceutical retail prices in Finland. My reduced form evidence shows that pharmaceutical manufacturers respond to a decrease in regulated pharmacy markups by increasing their wholesale...

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015173440

Deciphering the risk-return dynamics of pharmaceutical companies using the GARCH-M model

Kaur, Arvinder; Chavali, Kavita - 2025

This study focuses on the precise forecasting of stock price movement to determine returns, diversify risk, and demystify existing opportunities. It also aims to gauge the difference in terms of the stock volatility of various pharma companies before and during the pandemic era. The prediction...

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015409027

Can the size and duration of clinical trials in new drug applications predict post-approval safety warnings?

Clark, Jeremy; Menclova, Andrea Kutinova - 2025

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015394355

Evaluation of operational efficiency in China's pharmaceutical industry and analysis of environmental impacts

Sun, Jiaqiang; Rosli, Anita Binti; Daud, Adrian; Yan, Xia - 2025

The pharmaceutical industry is a cornerstone of national economies and plays a critical role in public health. However, China's pharmaceutical industry faces significant challenges, including regional disparities in development. The existing research on operational efficiency evaluation...

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015410063

A simulation-optimization approach for capacitated lot-sizing in a multi-level pharmaceutical tablets manufacturing process

Simonis, Michael; Nickel, Stefan - 2025

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015432994

Technological autonomy or global integration : navigating vaccine dependency in LMICs

Marin, Anabel; Morales, Jose - 2025

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015394620

Circular economy application in pharmaceutical supply chains in the UK : a holistic evolutionary game approach

Nami, Nazanin; Pishchulov, Grigory; Frota Neto, Joao … - 2025

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015433450

What economists should know about the 340B Drug Discounting Program

Courtemanche, Charles; Garuccio, Joseph - 2025

The 340B Drug Pricing Program was instituted to bolster the health care safety net without relying on taxpayer money. It allows participating health care facilities - most of which are hospitals - to purchase drugs filled at in-house or contracted external pharmacies at discounts from...

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015395374

Effects of debt financing decisions on profitability : a comparison of USA and Europe biopharmaceutical industry

Nkansah, Emmanuel - 2025

Debt financing is important for financing major investments in the biopharmaceutical industry. Debt financing allows companies to raise funds without giving up ownership or control through indenture and covenants of the company. In this study, I analyze the effects of debt financing decisions on...

Persistent link: https://ebvufind01.dmz1.zbw.eu/10015457531